Shots:

• Boehringer Ingelheim has reported data from P-III (FIBRONEER-IPF) study assessing the safety, efficacy & tolerability of nerandomilast (oral, BID) vs PBO for at least 52wks. to treat idiopathic pulmonary fibrosis (IPF) patients (n=1177)
• The study reached its 1EP of absolute change in forced vital capacity (mL) from baseline to wk.52. Complete results will be revealed during H1’25 and will form the basis of NDA submission to the regulatory authorities globally for the same
• Nerandomilast (BI 1015550) works by inhibiting phosphodiesterase 4B (PDE4B) and is also being studied for progressive pulmonary fibrosis (PPF). It was designated as a breakthrough therapy by the US FDA for IPF in 2022

Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim

Related News:- Boehringer Ingelheim Reports the Acquisition of Saiba Animal Health, Strengthening its R&D Portfolio Focusing on Animal Health

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com